miR-125a-5p expression is associated with the age of breast cancer patients

H. He*, F. Xu*, W. Huang¹, S.Y. Luo¹, Y.T. Lin¹, G.H. Zhang¹, Q. Du¹ and R.H. Duan¹

¹The State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, Changsha, China
²Department of Breast and Thyroid Surgery, The Second Xiangya Hospital of Central South University, Changsha, China

*These authors contributed equally to this study.
Corresponding author: R.H. Duan
E-mail: duanranhui@sklmg.edu.cn

Received September 15, 2015
Accepted November 2, 2015
Published December 22, 2015
DOI http://dx.doi.org/10.4238/2015.December.22.17

ABSTRACT. Dysregulated miR-125 observed in multiple cancer types has suggested that it is involved in malignant proliferation and invasion. However, the clinical significance of miR-125 in human breast cancer (BC) has not yet been fully elucidated. In the present study, the expression of miR-125a-5p/3p and miR-125b in 143 pairs of BC and normal adjacent tissues (NATs) was measured by real-time quantitative PCR, and the correlation between expression and clinicopathological features was explored. miR-125a-5p and miR-125b were significantly down-regulated in BC tissue samples compared with their matched NAT samples, while the difference in miR-125a-3p expression between BC tissues and NATs was not statistically significant. The expression level of miR-125a-5p was found to be significantly higher in younger patients (<35 years) than in older patients (≥35, \( P = 0.005 \)). When the patients...
were divided into three groups according to age (<35, 36-48, and ≥48 years), a gradual reduction in miR-125a-5p expression was observed in BC tissue samples that correlated to increases in age (P = 0.009). There were no significant correlations between miR-125 expression and other clinicopathological features including tumor size, histological grade, hormone receptor status, Her-2 status, and lymph node metastasis. Taken together, these findings suggest that miR-125a-5p may play an important role in BC progression in an age-dependent manner, and that the down-regulation of miR-125a-5p and miR-125b may serve as independent predictors for breast cancer.

Key words: MicroRNA-125; Breast cancer; Clinicopathology

INTRODUCTION

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide, with more than one million new cases diagnosed each year (Turkoz et al., 2013). BC is a heterogeneous disease due to its complicated etiology, which involves both genetic and environmental factors. Although improvements have been made in early detection and treatment for patients, BC is still the leading cause of cancer-related deaths in women (Wang et al., 2013). Therefore, a better understanding of the molecular mechanisms involved in BC development and progression is needed.

Micro-RNAs (miRNAs) are a class of endogenous, noncoding, single-stranded RNA molecules that are approximately 22 nucleotides long (Garzon et al., 2006). They post-transcriptionally regulate gene expression, and as such affect many normal biological processes such as cell proliferation, growth, and survival. Additionally, miRNAs play crucial roles in pathological processes including tumorigenesis, angiogenesis, and tumor invasion (Alvarez-Garcia and Miska, 2005). miR-125, which is a highly conserved miRNA found in diverse species from nematodes to humans, and can be found as one of three homologs: hsa-miR-125a, hsa-miR-125b-1, and hsa-miR-125b-2 (Shaham et al., 2012). Controversial properties of the members of the miR-125 family have been reported in different types of cancer, such as their potential contribution to the initiation and progression of cancers by acting as either tumor suppressors or oncogenes (Nishida et al., 2011; Bi et al., 2012; Vriens et al., 2012). In BC, miR-125a and miR-125b were reported to be down-regulated in several biopsy specimens, where they acted as tumor suppressors by mediating the ERBB2 and ERBB3 pathways and by targeting the ETS1 gene (Scott et al., 2007). Furthermore, miR-125a represses cell growth by targeting HuR in MCF-7 breast cancer cells (Guo et al., 2009), and miR-125b allele-specific regulation of BMPR1B contributes to breast cancer risk (Saetrom et al., 2009). Although functions of the miR-125 family in breast cancer cells have been widely studied in vitro, its involvement in clinical features of BC in vivo has not been fully elucidated.

In the current study, we investigated the expression levels of miR-125a-5p/3p and miR-125b in 143 paired samples of BC and adjacent noncancerous tissues and investigated the potential relationships between miR-125 levels and clinicopathological parameters of BC patients.
MATERIAL AND METHODS

Patients and tissues

Fresh BC tissues and matched normal adjacent tissues (NATs, >2 cm away from the location of the cancer tissue) were collected directly from surgery of consecutive BC patients after removal of the necessary amount of tissue for routine pathology examination at the Second Xiangya Hospital of Central South University (Changsha, China) from December 2009 to March 2011. In total, 143 patients with a median age of 48 years (range 29-77 years) were included in the study. The patient diagnoses included 137 invasive ductal carcinomas, 1 invasive adenosquamous carcinoma, and 5 invasive lobular carcinomas. None of the patients had received chemotherapy or radiotherapy prior to surgery. Tissue samples were immediately frozen in liquid nitrogen after surgical resection and sent directly to the laboratory to perform RNA extraction. The diagnosis and histological grades of each case were independently confirmed by two pathologists based on the World Health Organization tumor classification. Informed written consent was obtained from all patients included in this study, which was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University.

miRNA isolation from tissues

Total RNA was extracted using TRIzol Reagent (Life Technologies, Carlsbad, CA, USA) according to manufacturer instructions. RNA concentration and purity were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and samples with a 260/280 ratio of >1.8 were considered of acceptable purity. The RNA samples were then stored at -80°C until further use.

qRT-PCR detection of miRNA

A quantitative real-time PCR (qRT-PCR) assay was performed to detect and quantify mature miR-125. Specifically, SYBR® PrimeScript™ miRNA RT-PCR Kit (TaKaRaBio, Japan) was used to synthesize specific cDNA of miR-125 and RNU6B (as an internal control), and perform qRT-PCR according to the manufacturer protocol. The miRNA-specific forward primers were designed by using the Primer Premier 5.0 software, and the sequences were as follows: miR-125a-5p (5’-TCCCTGAGACCCTTTAACCTGTGA-3’), miR-125a-3p (5’-ACAGGTGAGGTTCTTGGGAGCC-3’), and miR-125b (5’-TCCCTGAGACCCCTAACTTGTA-3’). qRT-PCRs were performed on the CFX96™ Real-Time System (Bio-Rad, Hercules, CA, USA). The relative expression of the mature miRNA was normalized to RNU6B and calculated using the comparative cycle threshold (2^ΔΔCt) method.

Statistical analysis

Statistical analysis was performed with the SPSS software package, version 17.0 (SPSS Inc., USA). Data on the relative expression of miRNA are reported as means ± standard deviation. For correlation analysis of BC clinical features with the expression levels of the miR-125 family, two group comparisons were performed using the Mann-Whitney test, and more than two groups
were compared using one-way analysis of variance (ANOVA). A P value of <0.05 was considered as statistically significant. All significance tests were two-sided.

RESULTS

MiR-125 expression in BC patients

MiR-125 expression was measured in 143 pairs of tumor tissues and NATs from BC patients, and the expression values obtained were compared between the paired samples. We found that MiR-125a-5p was down-regulated in 67% (96/143) of BC tissue samples compared with their paired NAT samples. The normalized mean expression ± SD of miR-125a-5p in BC tumor samples was 0.78 ± 0.73 compared with 1.00 ± 0.64 in NAT samples (Figure 1A, P = 0.009). miR-125b was down-regulated in 90% (128/143) of BC tissue samples, and the normalized expression in BC tumor samples was 0.56 ± 1.36 compared with 1.00 ± 1.27 in NAT samples (Figure 1B, P < 0.001). miR-125a-3p was down-regulated in 55% (78/143) of BC tissue samples, but the difference in expression between BC tumor samples and NAT samples was not statistically significant (P = 0.656, data not shown).

![Figure 1](image-url)

Figure 1. Normalized expression levels of the miR-125 family in breast cancer and normal adjacent tissues. The expression of miR-125a-5p and miR-125b was lower in BC patients than in NATs (P = 0.009 and P < 0.0001, respectively). The expression was determined using the $2^{-\Delta\Delta Ct}$ method. BC, breast cancer tissue; NAT, normal adjacent tissue. Bars are reported as mean values with standard deviations.

Correlation of miR-125 expression with clinicopathological features of BC patients

To investigate the clinical significance of the down-regulated miR-125, the relationships between miR-125 family members and clinicopathological factors were assessed. As shown in Table 1, histological grade, hormone receptor status, Her-2 status, lymph node metastasis, and tumor size were not correlated with miR-125 expression. However, the expression level of miR-125a-5p was significantly higher in younger age patients (<35) than in older patients (≥35, P = 0.005). To better understand the relationship between miR-125a-5p expression and BC patient age, patients were...
miR-125 expression and age of breast cancer patients

divided into three groups: young BC patients (<35 years, N = 12), young to premenopausal patients (36-48 years, N = 54), and postmenopausal patients (≥48 years, N = 77). The results revealed that there was a gradual reduction in the expression of miR-125a-5p with increasing age (Figure 2).

**Table 1.** Relationship between relative expressions of miR-125 family members and clinicopathological features.

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>miR-125a-5p (2^(-ΔΔCt)) in tumor</th>
<th>miR-125a-3p (2^(-ΔΔCt)) in tumor</th>
<th>miR-125b (2^(-ΔΔCt)) in tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean ± SD</td>
<td>P value</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;35 years</td>
<td>12</td>
<td>1.62 ± 0.90</td>
<td>1.05 ± 0.35</td>
<td>0.85 ± 1.28</td>
</tr>
<tr>
<td>≥35 years</td>
<td>131</td>
<td>0.95 ± 0.75</td>
<td>1.29 ± 1.26</td>
<td>0.50 ± 0.55</td>
</tr>
<tr>
<td>Histologic grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>9</td>
<td>0.89 ± 0.32</td>
<td>0.83 ± 0.57</td>
<td>0.39 ± 0.25</td>
</tr>
<tr>
<td>II</td>
<td>108</td>
<td>1.00 ± 0.82</td>
<td>1.29 ± 1.14</td>
<td>0.52 ± 0.65</td>
</tr>
<tr>
<td>III</td>
<td>14</td>
<td>0.96 ± 0.62</td>
<td>1.10 ± 1.01</td>
<td>0.53 ± 0.52</td>
</tr>
<tr>
<td>Estrogen receptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>62</td>
<td>0.95 ± 0.78</td>
<td>1.45 ± 1.47</td>
<td>0.54 ± 0.54</td>
</tr>
<tr>
<td>Positive</td>
<td>78</td>
<td>1.03 ± 0.76</td>
<td>1.10 ± 0.90</td>
<td>0.50 ± 0.67</td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>59</td>
<td>0.97 ± 0.81</td>
<td>1.36 ± 1.33</td>
<td>0.49 ± 0.48</td>
</tr>
<tr>
<td>Positive</td>
<td>80</td>
<td>1.00 ± 0.74</td>
<td>1.19 ± 1.09</td>
<td>0.54 ± 0.70</td>
</tr>
<tr>
<td>CerbB-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>95</td>
<td>0.98 ± 0.74</td>
<td>1.27 ± 1.10</td>
<td>0.45 ± 0.40</td>
</tr>
<tr>
<td>Positive</td>
<td>18</td>
<td>0.89 ± 0.68</td>
<td>1.23 ± 1.78</td>
<td>0.37 ± 0.37</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>71</td>
<td>0.97 ± 0.77</td>
<td>1.23 ± 1.36</td>
<td>0.46 ± 0.47</td>
</tr>
<tr>
<td>Present</td>
<td>72</td>
<td>1.02 ± 0.79</td>
<td>1.31 ± 1.05</td>
<td>0.61 ± 0.76</td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2 cm</td>
<td>42</td>
<td>0.96 ± 0.70</td>
<td>1.66 ± 1.69</td>
<td>0.58 ± 0.57</td>
</tr>
<tr>
<td>&gt;2 cm</td>
<td>97</td>
<td>1.00 ± 0.81</td>
<td>1.11 ± 0.92</td>
<td>0.49 ± 0.64</td>
</tr>
</tbody>
</table>

\[ΔΔCT = (Ct\ miR-125a-5p - Ct\ U6)\ cancer\ group\ - (Ct\ miR-125a-5p - Ct\ U6)\ control\ group.\]

**Figure 2.** Relative expression of miR-125a-5p for different age groups. Decreased expression of miR-125a-5p is seen with increasing age of breast cancer patients. The relative expression data were analyzed using the 2^(-ΔΔCt) method. ANOVA was used to determine significance.
DISCUSSION

miR-125 is an important miRNA family, whose members play fundamental roles in development and cell differentiation. Although miR-125 has been found to be down-regulated in BC, its clinical significance had not been investigated in a large patient population. In the present study, we performed a systematic evaluation of the clinical significance of miR-125 in 143 invasive BC cases. We observed a significant down-regulation in miR-125a-5p and miR-125b in BC tissues compared with NATs and further found a gradual reduction in miR-125a-5p expression that corresponded to increased patient age.

miR-125 family members have been demonstrated to be down-regulated in several diseases, highlighting their disease-suppressing properties in such pathologies; however, they also have disease-promoting properties in certain contexts (Sun et al., 2013). In BC, miR-125b has been demonstrated to be a tumor suppressor by down-regulating ERBB2 and ERBB3. It has further been shown that circulating miR-125b expression is associated with resistance of breast cancer cells, implicating it as a target for anticancer strategies (Wang et al., 2012). Moreover, in contrast to its tumor-suppressive properties, a recent study found that miR-125b could also induce metastasis of human breast cancer cells by targeting STARD13 (STAR-related lipid transfer domain containing 13) (Tang et al., 2012). These controversial properties of the miR-125 in BC suggest that miR-125 plays diverse roles in BC pathogenesis and progression, and therefore the underlying mechanism requires further investigation.

BC accounts for approximately 23% of all female malignancies, and while the incidence in younger women is low (<6%), these cancers tend to be more aggressive and are associated with unfavorable prognoses (Gabriel and Domchek, 2010; Narod, 2012; Kataoka et al., 2014). Previous studies have compared molecular features of BC to age and have shown that BC tumors in young women have distinct gene expression profiles and deregulated signaling pathways (Anders et al., 2008; Pirone et al., 2012; Colak et al., 2013; Peña-Chilet et al., 2014). The up-regulated miR-125a-5p in younger patients indicates that miR-125a-5p may play an important role in BC development in an age-dependent manner, although its effects and possible targets need to be further elucidated.

In conclusion, our data suggest that miR-125a-5p plays an important role in BC progression according to age and that the down-regulation of miR-125a-5p and miR-125b may serve as independent predictors for breast cancer.

Conflicts of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Research supported in part by the National Natural Science Foundation of China (grants #81172513, #81071028 and #81571253) and the Program for New Century Excellent Talents (grant #7603230006)

REFERENCES
